WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 885 - Thirty-fifth Report
(1999; 168 pages) [Spanish] View the PDF document
Table of Contents
View the documentWHO Expert Committee on Specifications for Pharmaceutical Preparations
View the document1. Introduction
Open this folder and view contents2. The international pharmacopoeia and related issues
Close this folder3. International Chemical Reference Substances and Infrared Reference Spectra
View the document3.1 Establishment of International Chemical Reference Substances
View the document3.2 International Infrared Reference Spectra
View the document3.3 Use of International Chemical Reference Substances and Infrared Reference Spectra
View the document3.4 Guidelines for the establishment, maintenance and distribution of chemical reference substances
Open this folder and view contents4. Quality control - national laboratories
Open this folder and view contents5. Good manufacturing practices
Open this folder and view contents6. Quality systems and inspection
Open this folder and view contents7. Other quality assurance topics
Open this folder and view contents8. Nomenclature and terminology
Open this folder and view contents9. Legal aspects of pharmaceuticals
Open this folder and view contents10. Regulatory issues
Open this folder and view contents11. Training activities
View the document12. Pharmaceuticals contaminated with diethylene glycol
View the documentAcknowledgements
View the documentReferences
View the documentAnnex 1. List of available International Chemical Reference Substances1
View the documentAnnex 2. List of available International Infrared Reference Spectra1
Open this folder and view contentsAnnex 3. General guidelines for the establishment, maintenance and distribution of chemical reference substances
Open this folder and view contentsAnnex 4. Good manufacturing practices: authorized person - role, functions and training
Open this folder and view contentsAnnex 5. Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients
Open this folder and view contentsAnnex 6. Guidelines for inspection of drug distribution channels
View the documentAnnex 7. Good pharmacy practice in community and hospital pharmacy settings
Open this folder and view contentsAnnex 8. National drug regulatory legislation: guiding principles for small drug regulatory authorities
Open this folder and view contentsAnnex 9. Provisional guidelines for developing training programmes: inspection and examination of counterfeit pharmaceuticals
View the documentWorld Health Organization Technical Report Series
View the documentSelected WHO Publications of Related Interest
View the documentBack Cover
 

3.2 International Infrared Reference Spectra

The Committee adopted 7 new International Infrared Reference Spectra.1 A total of 69 spectra are now available from the WHO Collaborating Centre for Chemical Reference Substances, Stockholm, Sweden (Annex 2). The contribution of the WHO Collaborating Centre for International Infrared Reference Spectra, Zurich, Switzerland, which prepares the spectra, was acknowledged. It was suggested that consideration might also be given to the publication of the spectra separately, in reduced form, to accompany The international pharmacopoeia.

1 Amiloride hydrochloride, beclometasone dipropionate, calcium folinate, carbidopa, dexamethasone, dexamethasone acetate monohydrate, valproic acid.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014